Zhejiang Shengda Pharm - Asset Resilience Ratio
Zhejiang Shengda Pharm (603079) has an Asset Resilience Ratio of 0.56% as of September 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Zhejiang Shengda Pharm (603079) financial obligations for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2017–2024)
This chart shows how Zhejiang Shengda Pharm's Asset Resilience Ratio has changed over time. See Zhejiang Shengda Pharm shareholders equity for net asset value and shareholders' equity analysis.
Liquid Assets Composition Over Time
This chart breaks down Zhejiang Shengda Pharm's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see 603079 market cap overview.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 0% |
| Short-term Investments | CN¥12.02 Million | 0.56% |
| Total Liquid Assets | CN¥12.02 Million | 0.56% |
Asset Resilience Insights
- Limited Liquidity: Zhejiang Shengda Pharm maintains only 0.56% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Zhejiang Shengda Pharm Industry Peers by Asset Resilience Ratio
Compare Zhejiang Shengda Pharm's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK |
Drug Manufacturers - Specialty & Generic | 4.94% |
|
Jiangsu Hengrui Medicine Co Ltd
SHG:600276 |
Drug Manufacturers - Specialty & Generic | 0.16% |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC |
Drug Manufacturers - Specialty & Generic | 43.05% |
|
Changchun High & New Technology Industries Group Inc
SHE:000661 |
Drug Manufacturers - Specialty & Generic | 3.73% |
|
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062 |
Drug Manufacturers - Specialty & Generic | 1.18% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 0.96% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
Annual Asset Resilience Ratio for Zhejiang Shengda Pharm (2017–2024)
The table below shows the annual Asset Resilience Ratio data for Zhejiang Shengda Pharm.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | CN¥14.73K ≈ $2.16K |
CN¥1.79 Billion ≈ $261.25 Million |
-0.17pp |
| 2023-12-31 | 0.18% | CN¥3.01 Million ≈ $440.97K |
CN¥1.72 Billion ≈ $251.57 Million |
+0.17pp |
| 2021-12-31 | 0.00% | CN¥14.41K ≈ $2.11K |
CN¥1.76 Billion ≈ $258.25 Million |
-1.20pp |
| 2018-12-31 | 1.20% | CN¥15.02 Million ≈ $2.20 Million |
CN¥1.25 Billion ≈ $183.31 Million |
-7.93pp |
| 2017-12-31 | 9.13% | CN¥90.00 Million ≈ $13.17 Million |
CN¥985.98 Million ≈ $144.28 Million |
-- |
About Zhejiang Shengda Pharm
Zhejiang Shengda Bio-Pharm Co., Ltd. develops, produces, and sells food and feed additives for pharmaceutical, nutritional, food, and animal feed industry. It offers vitamins, such as biotin and folic acid; biological preservatives, including nisin, polylysine, and natamycin; and intermediate APIs. The company was incorporated in 1999 and is headquartered in Tiantai, China.